AbbVie lifts full-year profit outlook amid strong psoriasis drug demand

AbbVie has raised its full-year adjusted profit guidance to a range of $10.61-$10.65 per share, following a strong third quarter where net revenue climbed 9.1% to $15.78 billion, exceeding analyst estimates. This performance was primarily driven by robust demand for its immunology drugs Skyrizi and Rinvoq, with Rinvoq now projected to maintain patent exclusivity until 2037, four years longer than some prior expectations. The company also increased its quarterly cash dividend to $1.73 per share, signaling confidence in its pipeline and strategy to offset declining sales of its former blockbuster Humira due to biosimilar competition.

Analysis

AbbVie (ABBV) has significantly raised its full-year adjusted income outlook to $10.61-$10.65 per share, up from a prior forecast of $10.38-$10.58, following a robust third quarter. Net revenue climbed 9.1% year-over-year to $15.78 billion, surpassing analyst estimates, while adjusted EPS of $1.86 also exceeded Bloomberg consensus expectations of $1.77. This strong performance underscores effective operational execution and better-than-anticipated sales.

The outperformance was primarily driven by strong demand for key immunology treatments, Skyrizi and Rinvoq, which are central to AbbVie's strategy to offset declining Humira sales due to biosimilar competition. Rinvoq's patent exclusivity has been extended to 2037, four years longer than some previous analyst projections, providing a clearer runway for future growth. The company anticipates Skyrizi and Rinvoq to generate a combined $31 billion in revenue by 2027.

In a strong signal of confidence, AbbVie increased its quarterly cash dividend to $1.73 per share from $1.64, reflecting the business's strength and promising outlook. Despite the positive news, ABBV shares were oscillating around the flatline in premarket trading, though they have surged over 27% year-to-date and reached an all-time peak in September. The overall sentiment surrounding ABBV is strongly positive, with a per-ticker sentiment score of 0.8.

Key Decisions for Investors

• Investors should closely track the sales performance of Skyrizi and Rinvoq, as their continued growth is critical to offsetting Humira's decline and achieving the projected $31 billion combined revenue by 2027.
• The extended patent exclusivity for Rinvoq until 2037 provides significant long-term revenue visibility, which investors should factor into their valuation models and competitive landscape assessments.
• The increased quarterly dividend signals management's confidence in future cash flows and financial stability, making ABBV potentially attractive for income-focused portfolios.
• Despite strong fundamentals and positive guidance, investors should assess ABBV's current valuation given its over 27% year-to-date surge and recent all-time peak, considering potential for short-term consolidation.